Journal
BRITISH JOURNAL OF CANCER
Volume 117, Issue 8, Pages 1089-1098Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/bjc.2017.281
Keywords
apoptosis; acute myeloid leukaemia; BCL2; MDM2; XIAP
Categories
Funding
- Amgen
- Astra-Zeneca
- Bayer
- Blueprint Medicines
- Bristol Myers Squib
- Celgene
- Lilly
- Merck Serono
- Merck Sharp Dohme
- Novartis
- Roche/Genentech
- Pfizer
Ask authors/readers for more resources
Acute myeloid leukaemia (AML) is a molecularly and clinically heterogeneous disease, and its incidence is increasing as the populations in Western countries age. Despite major advances in understanding the genetic landscape of AML and its impact on the biology of the disease, standard therapy has not changed significantly in the last three decades. Allogeneic haematopoietic stem cell transplantation remains the best chance for cure, but can only be offered to a minority of younger fit patients. Molecularly targeted drugs aiming at restoring apoptosis in leukaemic cells have shown encouraging activity in early clinical trials and some of these drugs are currently being evaluated in randomised controlled trials. In this review, we discuss the current development of drugs designed to trigger cell death in AML.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available